FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues

Quantitative real-time PCR and Western blot methods were developed to assess neonatal Fc-receptor (FcRn) mRNA and protein expression in human FcRn transgenic mice, Swiss Webster mice, and in select human tissues. Additionally, FcRn turnover was evaluated via pulse-chase. FcRn mRNA expression was sig...

Full description

Bibliographic Details
Published in:	Biomolecules
Main Authors:	Tommy Li, Joseph P. Balthasar
Format:	Article
Language:	English
Published:	MDPI AG 2018-10-01
Subjects:	FcRn human FcRn transgenic mouse mRNA protein tissue expression
Online Access:	http://www.mdpi.com/2218-273X/8/4/115

Similar Items

FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia
by: Michael Sandhu, et al.
Published: (2025-08-01)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
by: Yihan Zhou, et al.
Published: (2023-06-01)

The neonatal Fc receptor (FcRn) is required for porcine reproductive and respiratory syndrome virus uncoating
by: Kang Yang, et al.
Published: (2025-01-01)

Prediction of human pharmacokinetics of Fc-engineered therapeutic monoclonal antibodies using human FcRn transgenic mice
by: Kenta Haraya, et al.
Published: (2025-12-01)

Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies
by: SuBin Lee, et al.
Published: (2025-07-01)

Megalin Orchestrates FcRn Endocytosis and Trafficking
by: Eileen Dahlke, et al.
Published: (2022-12-01)

Glycoengineering of plant-produced Pembrolizumab enhances FcRn binding and extends serum half-life in mice
by: Christine Joy I. Bulaon, et al.
Published: (2025-12-01)

FcRn-guided antigen trafficking enhances cancer vaccine efficacy
by: Mengyu Hong, et al.
Published: (2025-01-01)

The FcRn from gene to protein and function: comparison between species
by: Luz Belinda Ortiz-Alegría, et al.
Published: (2025-08-01)

Human FcRn Is a Two-in-One Attachment-Uncoating Receptor for Echovirus 18
by: Xiangpeng Chen, et al.
Published: (2022-08-01)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
by: Thomas Müller, et al.
Published: (2023-12-01)

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
by: Simone Mester, et al.
Published: (2021-01-01)

Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential
by: Sanghwan Ko, et al.
Published: (2025-04-01)

Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
by: Johannes Reusch, et al.
Published: (2024-12-01)

Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
by: E. Sally Ward, et al.
Published: (2022-06-01)

Impact of mAb-FcRn affinity on IgG transcytosis across human well-differentiated airway epithelium
by: Kohei Togami, et al.
Published: (2024-09-01)

FcRN receptor antagonists in the management of myasthenia gravis
by: Vinaya Bhandari, et al.
Published: (2023-08-01)

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
by: Trang T. Vu, et al.
Published: (2024-01-01)

FcRn-Driven Nanoengineered Mucosal Vaccine with Multi-Epitope Fusion Induces Robust Dual Immunity and Long-Term Protection Against <i>Brucella</i>
by: Tingting Tian, et al.
Published: (2025-05-01)

From promise to practice: evaluating the clinical impact of FcRn inhibition in IgG-mediated autoimmune rheumatic diseases
by: Chu Wei Yang, et al.
Published: (2025-10-01)

Prediction of the pharmacokinetics, pharmacodynamics and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model.
by: Manoranjenni eChetty, et al.
Published: (2015-01-01)

Oral uptake and persistence of the FnAb-8 protein characterized by in situ radio-labeling and PET/CT imaging
by: Qian Wang, et al.
Published: (2020-11-01)

Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice
by: Jerome Egli, et al.
Published: (2022-12-01)

Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis
by: Hui‐Ning Li, et al.
Published: (2025-08-01)

Human FcRn can mediate the transport across intestinal mucosal barrier and prolong the half-life of rabbit IgG in vivo
by: Guangchang Pang, et al.
Published: (2015-06-01)

Overexpression of bovine FcRn in mice enhances T-dependent immune responses by amplifying T helper cell frequency and germinal center enlargement in the spleen
by: Zita eSchneider, et al.
Published: (2015-07-01)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
by: Geert van Tetering, et al.
Published: (2020-12-01)

Lack of FcRn Impairs Natural Killer Cell Development and Functions in the Tumor Microenvironment
by: Diana Cadena Castaneda, et al.
Published: (2018-09-01)

A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph Nodes
by: Felix Stader, et al.
Published: (2024-08-01)

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network
by: Luqiong Wang, et al.
Published: (2025-10-01)

Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties
by: Nilufer P. Seth, et al.
Published: (2025-12-01)

Establishment an echovirus 6 infection model based on hFcRn transgenic mice
by: Fei Li, et al.
Published: (2025-10-01)

Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
by: Yvonne J. Rosenberg, et al.
Published: (2023-04-01)

Zika Virus Infection and Antibody Neutralization in FcRn Expressing Placenta and Engineered Cell Lines
by: Yanqun Xu, et al.
Published: (2022-11-01)

Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy
by: Qiqi Peng, et al.
Published: (2025-05-01)

Opinion: There’s been a flaw in our thinking.
by: Clark Lawrence Anderson
Published: (2014-10-01)

Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier
by: Jason Tien, et al.
Published: (2023-12-01)

Neonatal Fc receptor-targeted lignin-encapsulated porous silicon nanoparticles for enhanced cellular interactions and insulin permeation across the intestinal epithelium
by: João P. Martins, et al.
Published: (2022-03-01)

The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
by: Jia-Jun Cheng, et al.
Published: (2025-08-01)